Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2020-10-22 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting period. This type of disclosure regarding stock-based compensation and capital changes falls under the category of regulatory filings that do not fit into specific financial reporting categories like 10-K or IR, and is best classified as a general regulatory filing (RNS) or a specific corporate action announcement.
2020-10-22 Korean
상호변경안내
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding a change of company name (from Lumimicro to Vivozon Healthcare) following an extraordinary general meeting. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a regulatory announcement regarding corporate identity, it falls under the general regulatory filings category.
2020-10-22 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's representative director (CEO). It details the 'before' and 'after' status, the reason for the change (management efficiency), and the date of the board resolution. This falls directly under the category of board/management changes.
2020-10-22 Korean
[기재정정]주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity Classification · 100% confidence The document is a 'Correction Report' (정정신고) regarding a 'Major Report' (주요사항보고서) concerning the disposal of shares in another company (타법인 주식 및 출자증권 양도결정). It details changes to the payment date and transaction details. In the context of Korean corporate filings (DART system), this is a regulatory filing related to material corporate events, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually refers to full mergers/acquisitions) or other specialized reports.
2020-10-21 Korean
본점소재지변경
Regulatory Filings Classification · 95% confidence The document is a short, structured announcement regarding a change in the company's registered office address (본점소재지변경). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor does it relate to share transactions or governance reports. As it is a general regulatory announcement regarding corporate administrative changes, it falls under the RNS (Regulatory Filings) category.
2020-10-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) when an executive or major shareholder changes their shareholding status. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2020-10-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.